The findings of a study published this month in the Journal of Child and Adolescent Psychopharmacology may be cause for concern for Risperdal lawsuit plaintiffs, as well as parents whose children may be prescribed antipsychotics.
HealthDay News reported in April that Medicaid-insured youths in foster care and who may also be diagnosed with attention-deficit/hyperactivity disorder (ADHD) may be more likely to be treated with a drug from this class of medications, which includes Johnson & Johnson’s Risperdal. Included in the Journal study was data from 266,590 children between the ages of 2 and 17, who were enrolled in Medicaid during 2006.
According to researchers, who hailed from the University of Maryland in Baltimore, antipsychotics are typically used for 180 day-periods. Children aged between 2 and 12 years received the medication for a considerably longer period of time, at an average of 192 days, while adolescents from 13-17 years old were shown to take the medications for a period of 179 days. These numbers also varied on condition. Children on Medicaid who were treated for symptoms associated with ADHD took antipsychotics like Risperdal, which is marketed in its generic form as rispiridone, for an average of 250 days. Nearly one-third of foster care youths with this disorder took these medications, the study found. According to findings, “Exposure to atypical antipsychotics in Medicaid-insured youth, in particular for children in foster care and those diagnosed with ADHD, was substantial, warranting outcomes research for long-term effectiveness, safety, and oversight for appropriate cardiometabolic monitoring.” This recent study may be of particular interest to plaintiffs involved in Risperdal gynecomastia lawsuits against Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals Inc. Among other things, individuals in these cases allege that this medication may result in symptoms of gynecomastia, a condition referring to male breast growth and other side effects. It is noteworthy to add that many of 350 cases now pending in a consolidated litigation established in Pennsylvania’s Philadelphia Court of Common Pleas involve the treatment of Risperdal in children, despite the fact that its pediatric uses were not approved by the U.S. Food and Drug Administration (FDA) until 2006.
Contact our Firm to learn more about Risperdal lawsuits, and whether you may be eligible to file a claim over the antipsychotic. Dial the nationwide law firm of Bernstein Liebhard LLP today at .